Sökning: "astatine"
Visar resultat 1 - 5 av 17 avhandlingar innehållade ordet astatine.
1. Astatine-211 radioimmunotherapy of ovarian cancer. Therapeutic efficacy, myelotoxicity, andradiation dosimetry in an animal model
Sammanfattning : Alpha-particle emitting radionuclides have recently obtained an increased attention whenconsidering new strategies for treating disseminated cancer. Astatine (211At), that emits alphaparticleswith a mean path length of 62 μm, a mean linear energy transfer (LET) of 111keV/Mum, and a half-life of 7. LÄS MER
2. Alpha-radioimmunotherapy with At-211: Evaluations and imaging on normal tissues and tumors
Sammanfattning : Alpha-radioimmunotherapy (alpha-RIT) is an internal conformal radiotherapy at the cellular level using alpha-particle emitting radionuclides. Alpha-particles have a very short range in tissues (... LÄS MER
3. Development of targeted alpha therapy with Bi-213 and At-211 for the treatment of disseminated cancer
Sammanfattning : Radioimmunotherapy (RIT) is a type of targeted cancer therapy. The concept behind RIT is to deliver cytotoxic ionizing radiation to tumor cells by attaching radionuclides to tumor-specific antibodies. LÄS MER
4. Astatine-211 and Iodine Conjugates: Radiohalogenation and Preclinical Pharmacokinetics for Targeted and Pretargeted Radioimmunotherapy
Sammanfattning : Endoradiotherapy using labelled tumour specific-monoclonal antibodies in the therapy of malignant disease is a therapeutic modality that is coming of age. While clearly defined tumours can be treated with surgery and/or chemotherapy, occult metastases requires adjuvant systemic treatment, e.g. LÄS MER
5. Radioimmunotherapy of experimental ovarian cancer with Astatine-211. An in vivo model for consolidation treatment in women
Sammanfattning : About 850 new cases of ovarian cancer are diagnosed in Sweden every year. In 75 % of the patients the tumour has spread outside the ovaries. The standard treatment is surgery followed by six courses of combination chemotherapy. In spite of a very high frequency of clinical complete responses the 5-year survival is not satisfactory. LÄS MER